Leukemia
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.
Michela Ansuinelli, Nadia Peragine, Maria Stefania De Propris, Maria Cristina Puzzolo, Mariangela Di Trani, Loredana Elia, Cristina Skert, Roberto Cairoli, Simona Sica, Alessandro Rambaldi, Alessandra Tucci, Marco Cerrano, Daniele Vallisa, Valeria Cardinali, Antonino Mulè
Published: 202610.1038/s41375-025-02855-5
Abstract
In Ph+ acute lymphoblastic leukemia, frontline dasatinib plus blinatumomab (dasa+blina) is associated with long-term survival rates of 75-80%. The phase III GIMEMA ALL2820 trial has explored ponatinib with blinatumomab (pona+blina). In the present st…
Preview only. Read the full abstract at the source